Clinical trial Epi-RCHOP
A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL) patients treated by R-CHOP
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1/2 |
| Academic trial | Non |
| Sponsor | Lysarc |
| EudraCT Identifier | 2016-001499-31 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02889523 |
| Inclusion criteria | 1st line - DLBCL, transformed, follicular NHL grade IIIb |
| Last update |